Status:
COMPLETED
NR-SAFE: Safety of High-dose Nicotinamide Riboside (NR) in Parkinson's Disease
Lead Sponsor:
Haukeland University Hospital
Conditions:
Parkinson Disease
Eligibility:
All Genders
35+ years
Phase:
NA
Brief Summary
NR-SAFE is a double-blinded randomized safety study aiming to determine the safety and tolerability of nicotinamide riboside (NR) at a daily dose of 3000mg, in individuals with Parkinson's disease (PD...
Detailed Description
NR-SAFE is a double-blinded randomized safety study aiming to determine the safety and tolerability of nicotinamide riboside (NR) at a daily dose of 3000mg, in individuals with Parkinson's disease (PD...
Eligibility Criteria
Inclusion
- Age equal to or greater than 35 years and lower than 100 years at time of enrollment.
- Clinical diagnosis of idiopathic PD according to the MDS criteria.
- Hoehn and Yahr score \< 4 at enrolment.
Exclusion
- Dementia or other neurodegenerative disorder at baseline visit.
- Any psychiatric disorder that would interfere with compliance in the study.
- Any severe somatic illness that would make the individual unable to comply and participate in the study.
- Use of high dose vitamin B3 supplementation within 30 days of enrollment.
- Metabolic, neoplastic, or other physically or mentally debilitating disorder at baseline visit.
Key Trial Info
Start Date :
April 29 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05344404
Start Date
April 29 2022
End Date
July 1 2022
Last Update
August 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Haukeland University Hospital
Bergen, Norway